Boost Immunity to Track the Coronavirus if Some Modifications in its Structure have Occurred
The emergence of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) in 2003 and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in late 20121, we need to develop a universal vaccine able to boost immunity to track the coronavirus if some modifications in its structure have occurred by itself, this is what we are dealing nowadays with a virus capable of mutating its structure, while the immunity is standing still paralyzed facing the virus. Here, we report the preclinical trials of (CRCx3) and (CRCx2) vaccine candidate in inducing a high level of positive neutralizing antibodies as well as a cellular immune response in animal model to provide protection against SARS-CoV-2. Three-dose immunizations using 0.25 ml of (CRCx) vaccines with a 25 mm needle for three successive injections in 7days interval provided highly efficient protection against SARS-CoV-2. In addition, (CRCx) vaccines candidate exhibits efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of (CRCx) in a clinical trial.